On July 31, 2013, the United States Department of Justice announced that Wyeth Pharmaceuticals pleaded guilty to misbranding a drug and agreed to pay $490.9 million to resolve criminal and civil liability. The drug in question, Rapamune, was approved by the FDA in 1999 for use in preventing the body’s immune system from rejecting kidney transplants. Wyeth, however, allegedly trained its U.S. sales force to promote the drug for use in transplants of other organs, something that is ...
continue reading...Wyeth Pharmaceuticals Pleads Guilty to Criminal Misbranding of Rapamune
Posted December 27, 2013 in Product News and Recalls